![2024_cercle_bioalps 2024_cercle_bioalps](https://bioalps.org/app/uploads/2024/02/2024_cercle_bioalps.png)
AMAL Therapeutics raises 33.2 million dollars
![](https://bioalps.org/app/uploads/2018/07/icon-line-bicolor.png)
15.11.2018
Share this article
The Geneva-based startup just announced the completion of its Series B financing round, raising in total CHF 33.2 million.
Read Venturelab‘s interview of AMAL Therapeutics‘ CEO and Founder, Madiha Derouazi